BR0313209A - proteìnas que interagem com mk2 - Google Patents
proteìnas que interagem com mk2Info
- Publication number
- BR0313209A BR0313209A BRPI0313209-9A BR0313209A BR0313209A BR 0313209 A BR0313209 A BR 0313209A BR 0313209 A BR0313209 A BR 0313209A BR 0313209 A BR0313209 A BR 0313209A
- Authority
- BR
- Brazil
- Prior art keywords
- proteins
- interact
- inflammation
- relates
- bind
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 3
- 230000004054 inflammatory process Effects 0.000 abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40004402P | 2002-08-02 | 2002-08-02 | |
| PCT/US2003/023981 WO2004012660A2 (en) | 2002-08-02 | 2003-08-01 | Mk2 interacting proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313209A true BR0313209A (pt) | 2007-07-24 |
Family
ID=31495774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0313209-9A BR0313209A (pt) | 2002-08-02 | 2003-08-01 | proteìnas que interagem com mk2 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7364870B2 (https=) |
| EP (1) | EP1572092A4 (https=) |
| JP (1) | JP2006515159A (https=) |
| CN (1) | CN1735687A (https=) |
| AU (1) | AU2003257962A1 (https=) |
| BR (1) | BR0313209A (https=) |
| CA (1) | CA2494577A1 (https=) |
| IL (1) | IL166610A0 (https=) |
| MX (1) | MXPA05001364A (https=) |
| WO (1) | WO2004012660A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2617431T3 (en) | 2007-01-10 | 2017-07-10 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and applications therefor |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| EP2378875B1 (en) * | 2008-12-10 | 2018-05-30 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| EP2790018B1 (en) | 2011-12-05 | 2017-05-03 | Medical and Biological Laboratories Co., Ltd. | Method for detecting protein-protein interaction |
| WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| JP5904638B2 (ja) * | 2012-04-11 | 2016-04-13 | 株式会社日本マイクロニクス | 多層配線基板とその製造方法 |
| US11726081B2 (en) | 2019-02-15 | 2023-08-15 | Regents Of The University Of Minnesota | Methods to identify modulators of tau protein structure |
| US11656221B2 (en) * | 2019-06-11 | 2023-05-23 | Regents Of The University Of Minnesota | Methods to identify modulators of actin-binding proteins |
| WO2025215156A1 (en) * | 2024-04-11 | 2025-10-16 | Universitetet I Tromsø - Norges Arktiske Universitet | Biomarker of mk2 activity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5116944A (en) | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| US5414135A (en) | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
| US5624899A (en) | 1994-07-20 | 1997-04-29 | Genentech Inc. | Method for using Htk ligand |
| US6420338B1 (en) * | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
-
2003
- 2003-08-01 JP JP2004526272A patent/JP2006515159A/ja not_active Withdrawn
- 2003-08-01 US US10/523,014 patent/US7364870B2/en not_active Expired - Fee Related
- 2003-08-01 MX MXPA05001364A patent/MXPA05001364A/es not_active Application Discontinuation
- 2003-08-01 EP EP03767026A patent/EP1572092A4/en not_active Withdrawn
- 2003-08-01 CA CA002494577A patent/CA2494577A1/en not_active Withdrawn
- 2003-08-01 WO PCT/US2003/023981 patent/WO2004012660A2/en not_active Ceased
- 2003-08-01 AU AU2003257962A patent/AU2003257962A1/en not_active Withdrawn
- 2003-08-01 CN CNA038237008A patent/CN1735687A/zh not_active Withdrawn
- 2003-08-01 BR BRPI0313209-9A patent/BR0313209A/pt not_active IP Right Cessation
-
2005
- 2005-01-31 IL IL16661005A patent/IL166610A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003257962A1 (en) | 2004-02-23 |
| US7364870B2 (en) | 2008-04-29 |
| EP1572092A4 (en) | 2007-09-05 |
| JP2006515159A (ja) | 2006-05-25 |
| IL166610A0 (en) | 2006-01-15 |
| EP1572092A2 (en) | 2005-09-14 |
| US20060094101A1 (en) | 2006-05-04 |
| WO2004012660A2 (en) | 2004-02-12 |
| WO2004012660A3 (en) | 2005-10-20 |
| CA2494577A1 (en) | 2004-02-12 |
| MXPA05001364A (es) | 2005-08-03 |
| CN1735687A (zh) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0316438B8 (pt) | uso de eritropoietina em doenças cardíacas | |
| PT1049767E (pt) | Coelho transgenico que expressa uma lipoproteina (a) humana funcional | |
| BRPI0613358A8 (pt) | ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência | |
| BR0313209A (pt) | proteìnas que interagem com mk2 | |
| MY138140A (en) | N-aroylphenylalanine derivatives | |
| UY26058A1 (es) | Compuestos utiles como antiinflamatorios ley 17.164 art. 127 | |
| BR112015027319A2 (pt) | métodos e composições para modular a expressão de apolipoproteína (a) | |
| EE9900481A (et) | Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks | |
| AR064456A1 (es) | Anticuerpos cd 44 | |
| BR9809819A (pt) | Compostos e métodos para a inibição da expressão de vcam-1 | |
| BR0015026A (pt) | Indóis substituìdos para a modulação da atividade de nfkb | |
| ECSP099058A (es) | Proteínas de enlace multivalente de cadena simple de con función efectora | |
| MXPA03010487A (es) | Derivados de diarilurea utiles como agentes antiinflamatorios. | |
| ECSP099688A (es) | Moléculas y métodos para modular la pro-proteína | |
| UY26929A1 (es) | Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis | |
| EP1654104A4 (en) | MILLING LIBRARY AND COMPUTER-IMPLEMENTED METHOD FOR THE EFFICIENT SELECTION OF PANELS FOR FULFILLING CRITERIA | |
| BR9810121A (pt) | Utilização do acido petroselìnico nativo ou esterificado | |
| PT1485080E (pt) | Utilização de adapaleno para o tratamento de desordens dermatológicas | |
| MX9702797A (es) | Agentes de enlace a cd23. | |
| BR0114526A (pt) | Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares | |
| BRPI0410876B8 (pt) | composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão | |
| BR9913855A (pt) | 1-2-3-4- tetrahidroquinolinas substituìdas na posição 2 e substituìdas na posição 4 com amino como inibidores de cetp | |
| BR0113661A (pt) | Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2 | |
| MY126972A (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines | |
| BRPI0416544A (pt) | proteìna de ligação de gag |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8AANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |